-
1
-
-
10744233716
-
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
-
O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
-
(2003)
N Engl J Med
, vol.348
, pp. 994-1004
-
-
O'Brien, S.G.1
Guilhot, F.2
Larson, R.A.3
-
2
-
-
80055070888
-
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
-
Cortes JE, Kantarjian HM, Brümmendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011, 118:4567-4576.
-
(2011)
Blood
, vol.118
, pp. 4567-4576
-
-
Cortes, J.E.1
Kantarjian, H.M.2
Brümmendorf, T.H.3
-
3
-
-
84899072118
-
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
-
Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood 2014, 123:2317-2324.
-
(2014)
Blood
, vol.123
, pp. 2317-2324
-
-
Shah, N.P.1
Guilhot, F.2
Cortes, J.E.3
-
4
-
-
36348968931
-
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
-
Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110:3540-3546.
-
(2007)
Blood
, vol.110
, pp. 3540-3546
-
-
Kantarjian, H.M.1
Giles, F.2
Gattermann, N.3
-
5
-
-
49249121723
-
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
-
Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008, 26:3204-3212.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3204-3212
-
-
Shah, N.P.1
Kantarjian, H.M.2
Kim, D.W.3
-
6
-
-
79251546724
-
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
-
Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011, 117:1141-1145.
-
(2011)
Blood
, vol.117
, pp. 1141-1145
-
-
Kantarjian, H.M.1
Giles, F.J.2
Bhalla, K.N.3
-
7
-
-
84887127701
-
A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias
-
Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 2013, 369:1783-1796.
-
(2013)
N Engl J Med
, vol.369
, pp. 1783-1796
-
-
Cortes, J.E.1
Kim, D.W.2
Pinilla-Ibarz, J.3
-
8
-
-
84923643914
-
Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial
-
(abstract).
-
Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE trial. Blood 2014, 124:3135. (abstract).
-
(2014)
Blood
, vol.124
, pp. 3135
-
-
Cortes, J.E.1
Kim, D.W.2
Pinilla-Ibarz, J.3
-
9
-
-
84893527395
-
Impact of baseline (BL) mutations, including low-level and compound mutations, on ponatinib response and end of treatment (EOT) mutation analysis in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML)
-
(abstract).
-
Deininger MW, Shah NP, Cortes JE, et al. Impact of baseline (BL) mutations, including low-level and compound mutations, on ponatinib response and end of treatment (EOT) mutation analysis in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML). Blood 2013, 122:652. (abstract).
-
(2013)
Blood
, vol.122
, pp. 652
-
-
Deininger, M.W.1
Shah, N.P.2
Cortes, J.E.3
-
10
-
-
0021336851
-
Prognostic discrimination in "good-risk" chronic granulocytic leukemia
-
Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984, 63:789-799.
-
(1984)
Blood
, vol.63
, pp. 789-799
-
-
Sokal, J.E.1
Cox, E.B.2
Baccarani, M.3
-
11
-
-
84881298446
-
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
-
Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013, 122:872-884.
-
(2013)
Blood
, vol.122
, pp. 872-884
-
-
Baccarani, M.1
Deininger, M.W.2
Rosti, G.3
-
12
-
-
84865864744
-
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)
-
Hanfstein B, Müller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 2012, 26:2096-2102.
-
(2012)
Leukemia
, vol.26
, pp. 2096-2102
-
-
Hanfstein, B.1
Müller, M.C.2
Hehlmann, R.3
-
13
-
-
84862907694
-
Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
-
Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012, 30:232-238.
-
(2012)
J Clin Oncol
, vol.30
, pp. 232-238
-
-
Marin, D.1
Ibrahim, A.R.2
Lucas, C.3
-
14
-
-
77953691179
-
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
-
Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362:2251-2259.
-
(2010)
N Engl J Med
, vol.362
, pp. 2251-2259
-
-
Saglio, G.1
Kim, D.W.2
Issaragrisil, S.3
-
15
-
-
77953725855
-
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
-
Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362:2260-2270.
-
(2010)
N Engl J Med
, vol.362
, pp. 2260-2270
-
-
Kantarjian, H.1
Shah, N.P.2
Hochhaus, A.3
-
16
-
-
84866175467
-
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial
-
Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012, 30:3486-3492.
-
(2012)
J Clin Oncol
, vol.30
, pp. 3486-3492
-
-
Cortes, J.E.1
Kim, D.W.2
Kantarjian, H.M.3
-
17
-
-
77958595179
-
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
-
Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010, 116:3758-3765.
-
(2010)
Blood
, vol.116
, pp. 3758-3765
-
-
Hughes, T.P.1
Hochhaus, A.2
Branford, S.3
-
18
-
-
84893136765
-
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
-
Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014, 123:494-500.
-
(2014)
Blood
, vol.123
, pp. 494-500
-
-
Jabbour, E.1
Kantarjian, H.M.2
Saglio, G.3
-
19
-
-
84897007532
-
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
-
Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014, 123:1353-1360.
-
(2014)
Blood
, vol.123
, pp. 1353-1360
-
-
Hughes, T.P.1
Saglio, G.2
Kantarjian, H.M.3
-
21
-
-
84874000814
-
BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib
-
Kim DD, Lee H, Kamel-Reid S, Lipton JH BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib. Br J Haematol 2013, 160:630-639.
-
(2013)
Br J Haematol
, vol.160
, pp. 630-639
-
-
Kim, D.D.1
Lee, H.2
Kamel-Reid, S.3
Lipton, J.H.4
-
22
-
-
84946832907
-
-
East Hanover, NJ, (accessed April 5, 2016).
-
Tasigna [package insert] 2015, Novartis Pharmaceuticals Corporation, East Hanover, NJ, (accessed April 5, 2016). https://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf.
-
(2015)
Tasigna [package insert]
-
-
-
23
-
-
84923682203
-
Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients
-
Knickerbocker R, Dorer DJ, Haluska FG, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Blood 2014, 124:4546.
-
(2014)
Blood
, vol.124
, pp. 4546
-
-
Knickerbocker, R.1
Dorer, D.J.2
Haluska, F.G.3
-
24
-
-
84923682210
-
Ponatinib efficacy and safety in patients with the T315I mutation: long-term follow-up of phase 1 and phase 2 (PACE) trials
-
(abstract).
-
Mauro MJ, Cortes JE, Hochhaus A, et al. Ponatinib efficacy and safety in patients with the T315I mutation: long-term follow-up of phase 1 and phase 2 (PACE) trials. Blood 2014, 124:4552. (abstract).
-
(2014)
Blood
, vol.124
, pp. 4552
-
-
Mauro, M.J.1
Cortes, J.E.2
Hochhaus, A.3
-
25
-
-
84893181293
-
Abl family kinases regulate endothelial barrier function in vitro and in mice
-
Chislock EM, Pendergast AM Abl family kinases regulate endothelial barrier function in vitro and in mice. PLoS One 2013, 8:e85231.
-
(2013)
PLoS One
, vol.8
, pp. e85231
-
-
Chislock, E.M.1
Pendergast, A.M.2
-
26
-
-
84880692698
-
Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival
-
Chislock EM, Ring C, Pendergast AM Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival. Proc Natl Acad Sci USA 2013, 110:12432-12437.
-
(2013)
Proc Natl Acad Sci USA
, vol.110
, pp. 12432-12437
-
-
Chislock, E.M.1
Ring, C.2
Pendergast, A.M.3
-
27
-
-
84897573995
-
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease
-
Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014, 32:424-430.
-
(2014)
J Clin Oncol
, vol.32
, pp. 424-430
-
-
Rousselot, P.1
Charbonnier, A.2
Cony-Makhoul, P.3
-
28
-
-
84879710913
-
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
-
Hochhaus A, Saglio G, Larson RA, et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2013, 121:3703-3708.
-
(2013)
Blood
, vol.121
, pp. 3703-3708
-
-
Hochhaus, A.1
Saglio, G.2
Larson, R.A.3
-
29
-
-
84940797444
-
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
-
Hughes TP, Saglio G, Quintás-Cardama A, et al. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia 2015, 29:1832-1838.
-
(2015)
Leukemia
, vol.29
, pp. 1832-1838
-
-
Hughes, T.P.1
Saglio, G.2
Quintás-Cardama, A.3
|